Ollin debuts with $100M and plans to challenge top-selling eye drugs

Ollin debuts with $100M and plans to challenge top-selling eye drugs

Backed by a trio of top venture firms, Ollin is working on a pair of medicines it believes can one-up Roche’s Vabysmo and Amgen’s Tepezza.

Ollin Biosciences Launches with $100 Million to Advance Next-Generation Ophthalmic Therapies

Ollin Biosciences has emerged from stealth with $100 million in initial financing. Ollin is assembling a robust pipeline of both clinical and late-stage preclinical programs, building upon validated biologies to better address unmet treatment needs in ophthalmology. “Our mission is to deliver best-in-disease therapies for patients whose sight is at risk,” said Jason Ehrlich, MD, PhD, co-founder and chief executive officer of Ollin. “With bispeci…

Ollin lands $100M to test eye drugs from Chinese partners and bring in more assets

Another US biotech has emerged with rights to experimental medicines that were created by China-based drug developers. On Wednesday, Austin, TX-based Ollin Biosciences debuted with $100 million in funding to create new ophthalmology treatments from ...

Ollin debuts with $100M and plans to challenge top-selling eye drugs – RamaOnHealthcare

The biotech is developing two eye drug prospects licensed from China-based drugmakers Innovent Biologics and VelaVigo.A new biotechnology startup is launching with plans to challenge some of the world’s best-selling eye medicines, armed with a pair of prospects already in, or approaching, clinical testing.Called Ollin Biosciences, the startup emerged from stealth on Wednesday with $100 [...]